The Discounted Cash Flow (DCF) valuation of Nektar Therapeutics (NKTR) is (71.51) USD. With the latest stock price at 62.99 USD, the upside of Nektar Therapeutics based on DCF is -213.5%.
Based on the latest price of 62.99 USD and our DCF valuation, Nektar Therapeutics (NKTR) is a sell. selling NKTR stocks now will result in a potential gain of 213.5%.
Note: valuation result may not be accurate due to the company's negative cashflows.
| Range | Selected | |
| WACC / Discount Rate | 5.9% - 8.6% | 7.3% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (251.72) - (42.37) | (71.51) |
| Upside | -499.6% - -167.3% | -213.5% |